Shield Therapeutics appoints Richard Jones as CFO
This article was originally published in Scrip
Shield Therapeutics, an independent speciality pharmaceutical company focused on the development of late-stage hospital products, has appointed Richard Jones chief financial officer. Mr Jones has 12 years' experience in corporate finance and broking, having most recently served as director and head of healthcare at Brewin Dolphin Investment Banking, where he advised healthcare companies on financial transactions.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.